Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Innoviva, Inc.
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
July 31, 2024
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
May 08, 2024
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva to Participate in the BofA Securities Health Care Conference
May 08, 2024
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
February 29, 2024
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 01, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
October 11, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
September 18, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 25, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 02, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 06, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 11, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Announces Retirement of Board Chairman
April 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Stock Trading Halted Today
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
March 13, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
February 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
November 30, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 09, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 08, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Completes Acquisition of La Jolla Pharmaceutical
August 22, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
LJPC
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
July 27, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
July 13, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Completes Acquisition of Entasis Therapeutics
July 11, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
July 08, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
ETTX
INVA
Innoviva to Acquire Entasis Therapeutics
May 23, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
ETTX
INVA
Innoviva Reports First Quarter 2022 Financial Results
April 27, 2022
From
Innoviva, Inc.
Via
Business Wire
Tickers
INVA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.